These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 21906460)

  • 1. [Metabolic disorder after androgen deprivation therapy in patients with prostate cancer].
    Yuan JQ; Zhang XW; Xu T; Wang XF
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2011 Aug; 33(4):468-72. PubMed ID: 21906460
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Metabolic impact of androgen deprivation therapy for prostate cancer].
    Andrès E; Eschwege P; Lang H; Moreau JL; Peiffert D; Thiery-Vuillemin A; Kleinclauss F
    Prog Urol; 2012 Sep; 22 Suppl 2():S39-47. PubMed ID: 23098789
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased risk of metabolic syndrome, diabetes mellitus, and cardiovascular disease in men receiving androgen deprivation therapy for prostate cancer.
    Kintzel PE; Chase SL; Schultz LM; O'Rourke TJ
    Pharmacotherapy; 2008 Dec; 28(12):1511-22. PubMed ID: 19025432
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolic and cardiovascular effects of androgen deprivation therapy.
    Hakimian P; Blute M; Kashanian J; Chan S; Silver D; Shabsigh R
    BJU Int; 2008 Dec; 102(11):1509-14. PubMed ID: 18727614
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endocrine complications of androgen-deprivation therapy in men with prostate cancer.
    Harle LK; Maggio M; Shahani S; Braga-Basaria M; Basaria S
    Clin Adv Hematol Oncol; 2006 Sep; 4(9):687-96. PubMed ID: 17099626
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy.
    Braga-Basaria M; Dobs AS; Muller DC; Carducci MA; John M; Egan J; Basaria S
    J Clin Oncol; 2006 Aug; 24(24):3979-83. PubMed ID: 16921050
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emerging cardiometabolic complications of androgen deprivation therapy.
    Choong K; Basaria S
    Aging Male; 2010 Mar; 13(1):1-9. PubMed ID: 20148744
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of side effects of androgen deprivation therapy.
    Grossmann M; Zajac JD
    Endocrinol Metab Clin North Am; 2011 Sep; 40(3):655-71, x. PubMed ID: 21889727
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiovascular and Metabolic Effects of Androgen-Deprivation Therapy for Prostate Cancer.
    Gupta D; Lee Chuy K; Yang JC; Bates M; Lombardo M; Steingart RM
    J Oncol Pract; 2018 Oct; 14(10):580-587. PubMed ID: 30312560
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolic syndrome and androgen deprivation therapy in metabolic complications of prostate cancer patients.
    Yuan JQ; Xu T; Zhang XW; Yu LP; Li Q; Liu SJ; Huang XB; Wang XF
    Chin Med J (Engl); 2012 Oct; 125(20):3725-9. PubMed ID: 23075732
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Androgen deprivation therapy in men with prostate cancer: how should the side effects be monitored and treated?
    Grossmann M; Zajac JD
    Clin Endocrinol (Oxf); 2011 Mar; 74(3):289-93. PubMed ID: 21092052
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular and metabolic complications during androgen deprivation: exercise as a potential countermeasure.
    Galvão DA; Taaffe DR; Spry N; Joseph D; Newton RU
    Prostate Cancer Prostatic Dis; 2009; 12(3):233-40. PubMed ID: 19488067
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Complications of androgen deprivation therapy in prostate cancer.
    Schwandt A; Garcia JA
    Curr Opin Urol; 2009 May; 19(3):322-6. PubMed ID: 19318949
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between androgen-deprivation therapy and incidence of diabetes among males with prostate cancer.
    Lage MJ; Barber BL; Markus RA
    Urology; 2007 Dec; 70(6):1104-8. PubMed ID: 18158027
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Androgen deprivation therapy: evidence-based management of side effects.
    Ahmadi H; Daneshmand S
    BJU Int; 2013 Apr; 111(4):543-8. PubMed ID: 23351025
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence of osteoporosis during long-term androgen deprivation therapy in patients with prostate cancer.
    Morote J; Morin JP; Orsola A; Abascal JM; Salvador C; Trilla E; Raventos CX; Cecchini L; Encabo G; Reventos J
    Urology; 2007 Mar; 69(3):500-4. PubMed ID: 17382153
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of hot flashes on quality of life in patients with prostate cancer treated with androgen deprivation therapy.
    Nishiyama T; Kanazawa S; Watanabe R; Terunuma M; Takahashi K
    Int J Urol; 2004 Sep; 11(9):735-41. PubMed ID: 15379937
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostate cancer, androgen deprivation therapy, obesity, the metabolic syndrome, type 2 diabetes, and cardiovascular disease: a review.
    Collier A; Ghosh S; McGlynn B; Hollins G
    Am J Clin Oncol; 2012 Oct; 35(5):504-9. PubMed ID: 21297430
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence and predictive factors for the development of de novo psychiatric illness in patients receiving androgen deprivation therapy for prostate cancer.
    DiBlasio CJ; Hammett J; Malcolm JB; Judge BA; Womack JH; Kincade MC; Ogles ML; Mancini JG; Patterson AL; Wake RW; Derweesh IH
    Can J Urol; 2008 Oct; 15(5):4249-56; discussion 4256. PubMed ID: 18814813
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Depression in men receiving androgen deprivation therapy for prostate cancer: a pilot study.
    Pirl WF; Siegel GI; Goode MJ; Smith MR
    Psychooncology; 2002; 11(6):518-23. PubMed ID: 12476433
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.